• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Keytruda

Magnifying glass focusing on womens health
Biotech

OSE turns up the heat on ovarian cancer with phase 2 win

Researchers linked maintenance use of the neo-epitope vaccine candidate and Keytruda to improvements over best supportive care.
Nick Paul Taylor May 22, 2026 7:14am
lung
Favicon Fierce Pharma

ASCO: Merck, Kelun's sac-TMT combo beats Keytruda by 65% on PFS

May 21, 2026 5:00pm
Graphic image of a pen signing a signature while two strangelooking business people cheer

Merck inks Keytruda supply pact to support Exelixis cancer trial

May 19, 2026 9:38am
green light go go ahead advance yes streetlight

Inhibrx’s OX40-Keytruda combo shows promise in early ph. 2 data

May 11, 2026 10:06am
dart board miss failure
Favicon Fierce Pharma

Merck's Welireg surprisingly fails in first-line kidney cancer

Apr 21, 2026 10:00am
Golfer devastated after just barely missing a putt

Immutep's ph. 3 failure surprises analysts, sinks stock

Mar 13, 2026 9:53am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings